ESMO专家共识声明(ECS):HER2低表达乳腺癌的定义、诊断和管理
2022至2023年间,欧洲肿瘤内科学会(ESMO)组织来自九个国家32位乳腺癌管理专家,围绕HER2低表达乳腺癌的生物学、病理诊断、转移性乳腺癌临床管理及临床试验设计四个主题进行虚拟共识构建,通过工作组起草、全体讨论修订和投票形成共识声明,并汇总支持证据。
要点
- 共识聚焦HER2低表达乳腺癌的生物学、病理诊断、转移性乳腺癌临床管理及临床试验设计。
- 共识由32位来自九个国家的多学科专家参与,先复习相关科学文献,再起草、讨论修订并投票。
- 声明旨在补充现行ESMO临床实践指南未详细覆盖的内容,并汇总支持证据与专家意见。
核心结论
- 基于新型抗HER2抗体药物偶联物临床试验证据,HER2低表达乳腺癌已成为可靶向的乳腺癌亚群,共识就此形成声明。
研究设计与样本
- ESMO于2022至2023年间开展虚拟共识构建流程,纳入来自九个国家的32位乳腺癌管理多学科专家。
- 专家分为四个工作组,分别针对HER2低表达乳腺癌的生物学、病理诊断、转移性乳腺癌临床管理及临床试验设计起草声明。
- 工作组先复习相关科学文献,声明经全体讨论修订后投票形成。
关键数值与推荐
- 共识主题包括HER2低表达乳腺癌的生物学、病理诊断、转移性乳腺癌临床管理及临床试验设计。
- 声明旨在覆盖现行ESMO临床实践指南未详细涉及的内容,并汇总支持证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human epidermal growth factor receptor 2 (HER2)-low breast cancer has recently emerged as a targetable subset of breast tumors, based on the evidence from clinical trials of novel anti-HER2 antibody-drug conjugates. This evolution has raised several biological and clinical questions, warranting the establishment of consensus to optimally treat patients with HER2-low breast tumors. Between 2022 and 2023, the European Society for Medical Oncology (ESMO) held a virtual consensus-building process focused on HER2-low breast cancer. The consensus included a multidisciplinary panel of 32 leading experts in the management of breast cancer from nine different countries. The aim of the consensus was to develop statements on topics that are not covered in detail in the current ESMO Clinical Practice Guideline. The main topics identified for discussion were (i) biology of HER2-low breast cancer; (ii) pathologic diagnosis of HER2-low breast cancer; (iii) clinical management of HER2-low metastatic breast cancer; and (iv) clinical trial design for HER2-low breast cancer. The expert panel was divided into four working groups to address questions relating to one of the four topics outlined above. A review of the relevant scientific literature was conducted in advance. Consensus statements were developed by the working groups and then presented to the entire panel for further discussion and amendment before voting. This article presents the developed statements, including findings from the expert panel discussions, expert opinion, and a summary of evidence supporting each statement.
引用
- Tarantino P, Viale G, Press MF, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol. 2023. PMID: 37269905. doi:10.1016/j.annonc.2023.05.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。